Sarepta Therapeutics Inc. (NASDAQ:SRPT)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a report issued on Tuesday. They presently have a $66.00 target price on the stock. Wedbush’s target price indicates a potential upside of 8.29% from the company’s previous close.
Several other research firms also recently commented on SRPT. Oppenheimer Holdings Inc. reiterated a “buy” rating and issued a $60.00 price objective on shares of Sarepta Therapeutics in a report on Sunday, July 17th. Jefferies Group set a $58.00 price objective on shares of Sarepta Therapeutics and gave the company a “hold” rating in a report on Sunday. Janney Montgomery Scott reiterated a “hold” rating on shares of Sarepta Therapeutics in a report on Tuesday, June 7th. Robert W. Baird reiterated a “buy” rating on shares of Sarepta Therapeutics in a report on Friday, June 10th. Finally, WBB Securities reiterated a “buy” rating and issued a $40.00 price objective on shares of Sarepta Therapeutics in a report on Wednesday, June 8th. One analyst has rated the stock with a sell rating, five have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the stock. Sarepta Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $54.86.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) traded up 0.89% during trading on Tuesday, reaching $61.49. 767,250 shares of the company traded hands. Sarepta Therapeutics has a 12 month low of $8.00 and a 12 month high of $63.73. The stock’s market capitalization is $2.95 billion. The company has a 50-day moving average of $36.93 and a 200-day moving average of $24.28.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its earnings results on Tuesday, July 19th. The company reported ($1.35) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.19) by $0.16. During the same period last year, the business posted ($0.87) EPS. Analysts forecast that Sarepta Therapeutics will post ($4.16) earnings per share for the current fiscal year.
In other Sarepta Therapeutics news, VP Jayant Aphale sold 35,000 shares of the stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $1,750,000.00. Following the completion of the sale, the vice president now owns 21,490 shares of the company’s stock, valued at approximately $1,074,500. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP David T. Howton sold 9,304 shares of the stock in a transaction that occurred on Monday, September 19th. The shares were sold at an average price of $50.00, for a total transaction of $465,200.00. Following the sale, the senior vice president now directly owns 11,168 shares of the company’s stock, valued at approximately $558,400. The disclosure for this sale can be found here. 10.90% of the stock is owned by insiders.
Hedge funds have recently added to or reduced their stakes in the stock. State Street Corp increased its stake in Sarepta Therapeutics by 54.0% in the first quarter. State Street Corp now owns 2,467,376 shares of the company’s stock worth $48,168,000 after buying an additional 865,658 shares in the last quarter. Franklin Resources Inc. purchased a new stake in Sarepta Therapeutics during the first quarter worth $13,506,000. A.R.T. Advisors LLC purchased a new stake in Sarepta Therapeutics during the first quarter worth $7,461,000. Eagle Asset Management Inc. purchased a new stake in Sarepta Therapeutics during the second quarter worth $6,756,000. Finally, Emerald Mutual Fund Advisers Trust purchased a new stake in Sarepta Therapeutics during the second quarter worth $4,712,000. 65.29% of the stock is owned by institutional investors and hedge funds.
About Sarepta Therapeutics
Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others.
Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.